Hepatitis C drug: US group opposes Gilead’s patent request in India

US drug-maker Gilead Sciences’ patent application on hepatitis C drug sofosbuvir has been opposed at the Indian Patent Office by legal group I-MAK — Initiative for Medicines, Access & Knowledge. aThe pre-grant opposition, where a patent application is opposed before a decision is taken, was filed at the Kolkata patent office.

Read Full Story>>